Esperion Therapeutics (ESPR) Announces Publication of Bempedoic Acid Data in LDL-C

November 28, 2016 4:32 PM EST
Get Alerts ESPR Hot Sheet
Trade ESPR Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Esperion Therapeutics, Inc. (Nasdaq: ESPR) announced the publication of “Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis,” by Stephen L. Pinkosky et al. in Nature Communications, available at: http://www.nature.com/articles/ncomms13457. The paper systematically outlines the experiments and analyses undertaken by Esperion and its collaborators to fully understand the mechanism of action for how bempedoic acid reduces LDL-C.

Bempedoic acid is a pro-drug that requires activation to the CoA form to inhibit adenosine triphosphate (ATP) citrate lyase, an important enzyme on the cholesterol biosynthesis pathway. The specific enzyme required for this activation was identified as acetyl-CoA synthetase long chain 1 (ACSVL1), found in the liver but not found in skeletal muscle. Since bempedoic acid has no activity in skeletal muscle there is minimal risk for the muscle-related adverse events that have been associated with the use of statins.

Importantly, ATP citrate lyase (ACL) inhibition, mediated by bempedoic acid, results in decreased cholesterol biosynthesis, up regulation of LDL receptors, and reduction in LDL-C levels. In addition, bempedoic acid also reduced the progression of atherosclerosis in preclinical models.

“We are pleased that the research conducted by our scientific team on the liver-specific mechanism of action for bempedoic acid has been recognized in Nature Communications, a journal whose prestige speaks to the high quality of our science and research. Bempedoic acid targets ACL, the key differentiating feature of the molecule and has also been shown to complement the effects of statins, which target HMG-CoA reductase,” said Tim Mayleben, president and chief executive officer of Esperion Therapeutics. “The publication of these results will provide the scientific and medical communities information to better understand both how bempedoic acid reduces elevated LDL-C, and why bempedoic acid appears to be associated with minimal risk for the muscle-related adverse events that have been associated with the use of statins.”



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Related Entities

Twitter

Add Your Comment